Preliminary Safety and Efficacy Results From a First-in-Human Phase 1 Clinical Study of ALLO-329, a Dual Anti-CD19/Anti-CD70 Allogeneic

• Post author:andrewkaretas
• Post published:November 9, 2026
• Post category:Dual/Scientific Publications

CAR T-Cell Therapy for Autoimmune Disease

Continue ReadingPreliminary Safety and Efficacy Results From a First-in-Human Phase 1 Clinical Study of ALLO-329, a Dual Anti-CD19/Anti-CD70 Allogeneic

Off-the-shelf DLL3/CD70 dual CAR T cells with optimized site-specific integration for SCLC and neuroendocrine tumors

• Post author:andrewkaretas
• Post published:November 6, 2026
• Post category:DLL3/Scientific Publications

Continue ReadingOff-the-shelf DLL3/CD70 dual CAR T cells with optimized site-specific integration for SCLC and neuroendocrine tumors

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

• Post author:andrewkaretas
• Post published:July 15, 2026
• Post category:CD70/Scientific Publications

Continue ReadingAllogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Cytokine-Driven Divergence Between Allogeneic CAR-T Platforms

• Post author:andrewkaretas
• Post published:May 13, 2026
• Post category:PLATFORM/Scientific Publications

Continue ReadingCytokine-Driven Divergence Between Allogeneic CAR-T Platforms

Preclinical Evaluation of Allogeneic BCMA/CD70 Dual CAR T Cells for High-Risk Multiple Myeloma

• Post author:andrewkaretas
• Post published:April 20, 2026
• Post category:BCMA/Scientific Publications

Continue ReadingPreclinical Evaluation of Allogeneic BCMA/CD70 Dual CAR T Cells for High-Risk Multiple Myeloma

First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy: The Pivotal, Randomized, Open-Label Phase 2 ALPHA3 Study

• Post author:andrewkaretas
• Post published:December 31, 2025
• Post category:CD19/Scientific Publications

Continue ReadingFirst-Line Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy: The Pivotal, Randomized, Open-Label Phase 2 ALPHA3 Study

ALLO-316 in Advanced Clear Cell Renal Cell Carcinoma: Updated Results From the Phase 1 TRAVERSE Study

• Post author:andrewkaretas
• Post published:June 1, 2025
• Post category:CD70/Scientific Publications

Continue ReadingALLO-316 in Advanced Clear Cell Renal Cell Carcinoma: Updated Results From the Phase 1 TRAVERSE Study

ALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts)  With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD)  After Response to Standard Therapy

• Post author:andrewkaretas
• Post published:June 1, 2025
• Post category:CD19/Scientific Publications

Continue ReadingALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts)  With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD)  After Response to Standard Therapy

Allogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies

• Post author:andrewkaretas
• Post published:February 12, 2025
• Post category:CD19/Scientific Publications

Continue ReadingAllogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies

Supplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies

• Post author:andrewkaretas
• Post published:February 12, 2025
• Post category:CD19/Scientific Publications

Continue ReadingSupplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies